Biogen Inc.
225 Binney Street
Cambridge, MA 02142
United States
617 679 2000
https://www.biogen.com
版塊: Healthcare
行業: Drug Manufacturers - General
全職員工: 7,570
高階主管
| 名稱 | 頭銜 | 支付 | 行使價 | 出生年份 |
|---|---|---|---|---|
| Mr. Christopher A. Viehbacher | President, CEO & Director | 4.07M | 無 | 1961 |
| Mr. Michael R. McDonnell CPA | Executive VP & CFO | 2.21M | 無 | 1964 |
| Ms. Nicole Murphy | Head of Pharmaceutical Operations & Technology | 1.45M | 無 | 1973 |
| Ms. Susan H. Alexander Esq. | Executive VP & Chief Legal Officer | 1.95M | 無 | 1957 |
| Mr. Rachid Izzar | Head of Global Product Strategy & Commercialization | 1.27M | 無 | 1975 |
| Ms. Robin C. Kramer | Senior VP & Chief Accounting Officer | 無 | 無 | 1966 |
| Mr. Charles E. Triano | Senior VP & Head of Investor Relations | 無 | 無 | 無 |
| Ms. Natacha Gassenbach | Chief Communication Officer & Head of Corporate Affairs | 無 | 無 | 無 |
| Mr. Adam Keeney Ph.D. | Executive VP & Head of Corporate Development | 無 | 無 | 1977 |
| Dr. Ginger Gregory Ph.D. | Executive VP & Chief Human Resources Officer | 1.59M | 無 | 1968 |
描述
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
公司管治
截至 2024年5月1日 止，Biogen Inc. 的 ISS 管治質素評分為 7。 Pillar 分數正在審核中：10；董事會：5；股東權利：2；現金賠償：9。
